Command Palette

Search for a command to run...

Clinical Trials · NCT06039826

A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese

CompletedPhase 1Retatrutide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
46
Start date
Sep 2023
Locations
2 sites, United States
Primary endpoint
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time zero to 24 Hours Postdose (AUC0-24) of Ethinyl Estradiol
View Retatrutide compound reference